For something that can do what anatabine-citrate (was Anatabloc) can do, for a company in the right hands, the $70,000,000 debit is not a barrier. Especially if the Trump administration will not let the FDA get away with blatantly serving the commercial interests that long ago captured it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.